Table 3.

Association of immune cells and clinical outcome of treatment-naïve patients with NSCLC.

	Progression-free survival		Overall survival
	Months (95% CI)	p value	Months (95% CI)	p value
Clinical parameters
Age
(⩾68 versus <68)	3.7 (2.2–5.3) versus 4.3 (3.1–5.5)	0.59	6.9 (4.1–9.6) versus 9.2 (7.6–10.9)	0.04
Sex
(Male versus female)	ND	ND	ND	ND
Histology
(Non-SQ versus SQ)	3.9 (2.5–5.2) versus 4.3 (2.7–5.9)	0.65	7.2 (5.4–8.9) versus 9.9 (6.7–13.2)	0.61
Stage
(M1b versus non-M1b)	3.1 (2.3–3.9) versus 5.3 (3.4–7.3)	0.06	7.2 (5.2–9.1) versus 9.7 (6.4–13.1)	0.52
Immunological parameters (<versus ⩾ mean)
CD4+ T-cells	3.6 (1.9–5.2) versus 4.3 (2.9–5.5)	0.57	6.5 (4.2–8.7) versus 9.7 (7.0–12.4)	0.38
PD-1+ CD4+ T-cells	4.1 (2.6–5.6) versus 4.1 (2.6–5.6)	0.91	7.1 (5.0–9.2) versus 9.5 (6.4–12.5)	0.60
PD-L1+ CD4+ T-cells	3.9 (2.6–5.4) versus 4.2 (2.5–5.9)	0.73	7.1 (5.1–8.9) versus 10.9 (7.9–13.9)	0.32
CD8+ T-cells	4.8 (2.9–6.6) versus 3.3 (2.4–4.3)	0.16	9.2 (6.3–12.1) versus 7.1 (5.0–9.2)	0.89
PD-1 + CD8 + T-cells	4.8 (3.5–6.1) versus 2.8 (1.5–4.1)	0.02	9.9 (7.5–12.3) versus 6.1 (3.6–8.5)	0.23
PD-L1+ CD8+ T-cells	4.7 (3.3–6.0) versus 3.1 (1.8–4.3)	0.23	10.0 (7.4–12.6) versus 4.9 (3.6–6.2)	0.19
B-cells	3.4 (2.2–4.7) versus 4.9 (3.3–6.5)	0.20	7.0 (5.0–9.0) versus 9.2 (5.8–12.6)	0.52
PD-1+ B-cells	3.7 (2.5–4.8) versus 4.8 (2.8–6.8)	0.29	7.4 (5.6–9.4) versus 8.4 (4.7–12.2)	0.95
PD-L1+ B-cells	3.9 (2.8–4.9) versus 4.6 (2.2–6.9)	0.37	9.4 (7.2–11.5) versus 4.6 (2.2–7.0)	0.29
DC/monocytes	3.3 (1.2–5.5) versus 4.4 (3.4–5.5)	0.05	5.3 (2.7–7.8) versus 10.4 (8.1–11.7)	0.04
PD-1+ DC/monocytes	3.8 (2.6–5.1) versus 4.1 (2.6–5.5)	0.98	8.2 (5.9–10.4) versus 8.6 (5.9–11.3)	0.68
PD-L1+ DC/monocytes	3.9 (2.7–5.1) versus 4.4 (2.1–6.7)	0.53	7.8 (5.9–9.6) versus 8.1 (4.1–12.0)	0.64

CI, confidence intervals; DC, dendritic cell; N, number of patients; ND, not defined; NSCLC non-small cell lung cancer; PD-1, programmed cell death receptor 1; PD-L1, programmed death ligand 1; SQ, squamous.